ASH 2017: Highlights on Myeloma

Speaker: Christian Buske

Reporting from ASH 2017 on Myeloma, Christian Buske highlights two studies relevant to clinical practice. EMNO2/HO95 compares ASCT to VMP showing superiority of ASCT; ALCYONE compares D-VMP to VMP with positive results for the additional of daratumumab.

In the EMNO2/HO95 study patients were randomised to either ASCT or VMP with a 24% risk reduction in PFS observed for ASCT: ASCT remains the treatment of choice for younger patients. In the ALCYONE study, adding daratumumab to VMP for patients with newly diagnosed MM ineligible for transplant resulted in a 50% risk reduction for PFS - longer follow-up may show differences in OS. With the D-VMP therapy significant reduction in MRD positivity was also observed; several abstracts at ASH 2017 showed MRD negativity to be a powerful predictor for disease-free interval.


Autologous Stem Cell Transplantation Versus Bortezomib-Melphalan-Prednisone for Newly Diagnosed Multiple Myeloma: Second Interim Analysis of the Phase 3 EMN02/HO95 Study
Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE)